Melanoma Molecular Maps Projects


Targeted Therapy Database

A systematic collection of the scientific knowledge regarding the development of targeted therapy for melanoma. Since data are gathered in a computationally compatible fashion, the database can be utilized for the identification of prevalent therapeutic hypotheses based on the available evidence and for ranking treatments based on the patient's molecular profile (drug ranking system). In particular the TTD can be queried for the following purposes:

  1. To provide both basic researchers and clinical investigators with an unprecedented synopsis of the available scientific literature on the development of targeted therapy for melanoma;

  2. To obtain summaries of the current evidence on the relationship between each single molecule (or set of molecules) and the efficacy (toxicity) of a given therapeutic agent (or set of therapeutic agents);

  3. To match the patient/cancer molecular profile with the available scientific evidence on the targeted therapy of melanoma, thus developing a drug ranking system for the personalized treatment of melanoma.

Please click on the following links to open the TARGETED THERAPY DATABASE (TTD) and its User's Guide.

The second version of the Targeted Therapy Database (TTD) is now available, with more records on the personalized treatment of melanoma.


"Targeted Therapy Database (TTD): A Model To Match Patient's Molecular Profile With Current Knowledge On Cancer Biology". By: Mocellin S., Shrager J., Scolyer R., Pasquali S., Verdi D., Marincola F.M., Briarava M., Gobbel R., Rossi C., Nitti D.
PLoS One (2010), 5(8):e11965

Search the site

Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |

Melanoma News

Sentinel node biopsy in patients with primary cutaneous melanoma of any thickness: A cost-effectiveness analysis.
Serra-Arbeloa P, Rabines-Juárez ÁO, Álvarez-Ruiz MS, Guillén-Grima F
Surg Oncol. 2016 Sep;25(3):205-11.
PMID: 27566024 [PubMed - in process]

Epidemiology of cutaneous melanoma in Sweden - stage specific survival and rate of recurrence.
Rockberg J, Amelio JM, Taylor A, Jörgensen L, Ragnhammar P, Hansson J
Int J Cancer. 2016 Aug 26;():.
PMID: 27563839 [PubMed - as supplied by publisher]

Variations in supportive care needs of patients after diagnosis of localised cutaneous melanoma: a 2-year follow-up study.
Beesley VL, Smithers BM, O'Rourke P, Janda M, Khosrotehrani K, Green AC
Support Care Cancer. 2016 Aug 25;():.
PMID: 27562298 [PubMed - as supplied by publisher]

Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma .
Koskivuo I, Kemppainen J, Giordano S, Seppänen M, Veräjänkorva E, Vihinen P, Minn H
Acta Oncol. 2016 Aug 24;():1-5.
PMID: 27553064 [PubMed - as supplied by publisher]

Glutathione S-transferase M1 null genotype, household pesticides exposure and cutaneous melanoma.
Fortes C, Mastroeni S, Bottà G, Boffetta P, Antonelli G, Venanzetti F
Melanoma Res. 2016 Aug 18;():.
PMID: 27540835 [PubMed - as supplied by publisher]

NCBI's Disclaimer and Copyright notice